SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-054593
Filing Date
2023-11-24
Accepted
2023-11-24 16:45:52
Documents
12
Period of Report
2023-11-17
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K ny20015093x1_8k.htm   iXBRL 8-K 31336
  Complete submission text file 0001140361-23-054593.txt   168746

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrtx-20231117.xsd EX-101.SCH 3859
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrtx-20231117_lab.xml EX-101.LAB 22546
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrtx-20231117_pre.xml EX-101.PRE 16040
6 EXTRACTED XBRL INSTANCE DOCUMENT ny20015093x1_8k_htm.xml XML 4035
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 231437026
SIC: 2834 Pharmaceutical Preparations